Oral Minoxidil-Finasteride Composition for Hair Loss Compliance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for hair loss, such as topical minoxidil and finasteride, may have limitations such as rash, irritation, poor compliance, and inconsistent efficacy, particularly in severe cases.
Innovation Solution
A pharmaceutical package containing oral formulations of minoxidil and a 5-alpha reductase inhibitor, such as finasteride, is provided to enhance patient compliance and efficacy in treating hair loss, with the option of mixing the compositions immediately before administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If topical minoxidil and finasteride are used as separate treatments, then hair loss can be addressed, but patient compliance is reduced and administration is inconvenient
Solution Approach 1:
The patent combines two separate pharmaceutical compositions (minoxidil and finasteride) into a single unified oral composition. This merging eliminates the need for patients to manage multiple separate medications, thereby improving administration convenience and enhancing patient compliance while maintaining the therapeutic effects of both individual treatments
2Reliability
If multiple separate medications are prescribed for hair loss, then treatment efficacy can be achieved, but side effects and complexity increase
Solution Approach 1:
The patent merges minoxidil and finasteride into a single oral composition, reducing treatment complexity by eliminating the need to manage multiple separate medications. This unified approach maintains the combined therapeutic efficacy of both drugs while simplifying the treatment regimen and reducing the burden on patients
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combined oral administration of minoxidil and a 5-alpha reductase inhibitor, like finasteride, improves hair growth and reduces shedding, offering enhanced efficacy and convenience for patients.
Implementation Method 1
a pharmaceutical composition for oral administration comprising a therapeutically effective or prophylactically effective amount of minoxidil, or a similar antihypertensive vasodilator
Implementation Method 2
a pharmaceutical composition for oral administration comprising a therapeutically effective or prophylactically effective amount of a 5-alpha reductase inhibitor for treating or preventing hair loss in a subject
Data Source
AI summary
This disclosure relates to a single pharmaceutical composition comprising a therapeutically effective or prophylactically effective amount of both minoxidil, or a similar antihypertensive vasodilator, and a 5-alpha reductase inhibitor (in some embodiments, the 5-alpha reductase inhibitor is finasteride) for treating or preventing hair loss in a subject. This disclosure also relates to a pharmaceutical package comprising a pharmaceutical composition for oral administration of a therapeutically effective or prophylactically effective amount of minoxidil, or a similar antihypertensive vasodilator, and a pharmaceutical composition for oral administration comprising a therapeutically effective or prophylactically effective amount of a 5-alpha reductase inhibitor (in some embodiments, the 5-alpha reductase inhibitor is finasteride) for treating or preventing hair loss in a subject. The disclosure further provides methods of treating or preventing hair loss in a subject using the disclosed compositions and packages.